Drug
Endoxifen hydrochloride clinical trials
A product of Endoxifen; its studies count on that page too.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2011
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2011 (1)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2015 | 1 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 0 · Other 3
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses endoxifen hydrochloride is read from its arms, and is right about nine times in ten.
Testing it · 3
- Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast CancerActive, not recruitingPhase 2National Cancer Institute (NCI)NCT02311933Written as Endoxifen Hydrochloride
- Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast SurgeryActive, not recruitingPhase 1National Cancer Institute (NCI)NCT03317405Written as Endoxifen Hydrochloride
- Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast CancerActive, not recruitingPhase 1National Cancer Institute (NCI)NCT01327781Written as Endoxifen Hydrochloride
Codes
What other systems call endoxifen hydrochloride · ClinicalTrials.gg INT014562
- UNII (FDA) 308PA1L567ENDOXIFEN HYDROCHLORIDEConfirmed FDA, Wikidata
- Wikidata Q27255933endoxifen hydrochlorideConfirmed FDA, Wikidata
- NCI Thesaurus C95713Endoxifen HydrochlorideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 308PA1L567 | ENDOXIFEN HYDROCHLORIDE | Confirmed FDA, Wikidata |
| Wikidata | Q27255933 | endoxifen hydrochloride | Confirmed FDA, Wikidata |
| NCI Thesaurus | C95713 | Endoxifen Hydrochloride | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.